Circulating Permeability Factors in Primary Focal Segmental Glomerulosclerosis: A Review of Proposed Candidates

BioMed Research International

Volumn 2016, Issue , 2016, Pages

  Königshausen, Eva ^a   Sellin, Lorenz ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; CARDIOTROPHIN LIKE CYTOKINE FACTOR 1; CD40 ANTIBODY; CYTOKINE; PERMEABILITY FACTOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; PLASMA PROTEIN;

ANTIBODY DETECTION; CELL DAMAGE; DIAGNOSTIC VALUE; FOCAL GLOMERULOSCLEROSIS; HUMAN; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; NONHUMAN; PATHOGENESIS; PODOCYTE; PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEINURIA; REVIEW; ANIMAL; BLOOD; COMPLICATION; METABOLISM; NEPHROTIC SYNDROME; PERMEABILITY;

ANIMALS; BLOOD PROTEINS; CYTOKINES; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; NEPHROTIC SYNDROME; PERMEABILITY;

EID: 84971406256     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2016/3765608     Document Type: Review

References (71)

1. A. J. Collins, R. N. Foley, C. Herzog et al., "US renal data system 2010 annual data report, " American Journal of Kidney Diseases, vol. 57, no. 1, supplement 1, article A8, pp. e1-e526, 2011.
2. V. D. D'Agati, A. B. Fogo, J. A. Bruijn, and J. C. Jennette, "Pathologic classification of focal segmental glomerulosclerosis: a working proposal, " American Journal of Kidney Diseases, vol. 43, no. 2, pp. 368-382, 2004.
3. V. D. D'Agati, F. J. Kaskel, and R. J. Falk, "Focal segmental glomerulosclerosis, "The New England Journal of Medicine, vol. 365, no. 25, pp. 2398-2411, 2011.
4. A. B. Fogo, "Causes and pathogenesis of focal segmental glomerulosclerosis, " Nature Reviews Nephrology, vol. 11, no. 2, pp. 76-87, 2015.
5. C. Kitiyakara, J. B. Kopp, and P. Eggers, "Trends in the epidemiology of focal segmental glomerulosclerosis, " Seminars in Nephrology, vol. 23, no. 2, pp. 172-182, 2003.
6. R. J. Maas, J. K. Deegens, and J. F. Wetzels, "Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future, " Nephrology Dialysis Transplantation, vol. 29, no. 12, pp. 2207-2216, 2014.
7. F. Vincenti and G. M. Ghiggeri, "New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis, " American Journal of Transplantation, vol. 5, no. 6, pp. 1179-1185, 2005.
8. R. D. Davenport, "Apheresis treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation: reanalysis of published case-reports and case-series, " Journal of Clinical Apheresis, vol. 16, no. 4, pp. 175-178, 2001.
9. A. Matalon, G. S. Markowitz, R. E. Joseph et al., "Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipients, " Clinical Nephrology, vol. 56, no. 4, pp. 271-278, 2001.
10. S. W. Zimmerman and S. Mann, "Increased urinary protein excretion in the rat produced by serum from a patient with recurrent focal glomerular sclerosis after renal transplantation, " Clinical Nephrology, vol. 22, no. 1, pp. 32-38, 1984.
11. M. Sharma, R. Sharma, S. R. Reddy, E. T. McCarthy, and V. J. Savin, "Proteinuria after injection of human focal segmental glomerulosclerosis factor, " Transplantation, vol. 73, no. 3, pp. 366-372, 2002.
12. M. D. C. Avila-Casado, I. Perez-Torres, A. Auron, V. Soto, T. I. Fortoul, and J. Herrera-Acosta, "Proteinuria in rats induced by serum from patients with collapsing glomerulopathy, " Kidney International, vol. 66, no. 1, pp. 133-143, 2004.
13. V. J. Savin, R. Sharma, M. Sharma et al., "Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis, " The New England Journal of Medicine, vol. 334, no. 14, pp. 878-883, 1996.
14. M. J. Kemper, G. Wolf, and D. E. Müller-Wiefel, "Transmission of glomerular permeability factor from a mother to her child, " The New England Journal of Medicine, vol. 344, no. 5, pp. 386-387, 2001.
15. L. Gallon, J. Leventhal, A. Skaro, Y. Kanwar, and A. Alvarado, "Resolution of recurrent focal segmental glomerulosclerosis after retransplantation, " The New England Journal of Medicine, vol. 366, no. 17, pp. 1648-1649, 2012.
16. J. Dantal, E. Bigot, W. Bogers et al., "Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome, " The New England Journal of Medicine, vol. 330, no. 1, pp. 7-14, 1994.
17. M. Sharma, R. Sharma, E. T. Mccarthy, and V. J. Savin, "'The FSGSfactor:' enrichment and invivo effectof activity fromfocal segmental glomerulosclerosis plasma, " Journal of the American Society of Nephrology, vol. 10, no. 3, pp. 552-561, 1999.
18. V. J. Savin, E. T. McCarthy, R. Sharma, D. Charba, and M. Sharma, "Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity, " Translational Research, vol. 151, no. 6, pp. 288-292, 2008.
19. J. J. Harris, H. J. McCarthy, L. Ni et al., "Active proteases in nephrotic plasma lead to a podocin-dependent phosphorylation of VASP in podocytes via protease activated receptor-1, " Journal of Pathology, vol. 229, no. 5, pp. 660-671, 2013.
20. N. Kachurina, C. F. Chung, E. Benderoff et al., "Novel unbiased assay for circulating podocyte-toxic factors associated with recurrent focal segmental glomerulosclerosis, " American Journal of Physiology-Renal Physiology, 2015.
21. T. Plesner, M. Ploug, V. Ellis et al., "The receptor for urokinasetype plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils, " Blood, vol. 83, no. 3, pp. 808-815, 1994.
22. A. Estreicher, J. Muhlhauser, J.-L. Carpentier, L. Orci, and J.-D. Vassalli, "Thereceptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes, " Journal of Cell Biology, vol. 111, no. 2, pp. 783-792, 1990.
23. A. Nykjaer, B. Moller, R. F. Todd III et al., "Urokinase receptor. An activation antigen in human T lymphocytes, " The Journal of Immunology, vol. 152, no. 2, pp. 505-516, 1994.
24. E. S. Barnathan, A. Kuo, K. Karikó et al., "Characterization of human endothelial cell urokinase-type plasminogen activator receptor protein and messenger RNA, " Blood, vol. 76, no. 9, pp. 1795-1806, 1990.
25. M. Thuno, B. MacHo, and J. Eugen-Olsen, "SuPAR: the molecular crystal ball, " Disease Markers, vol. 27, no. 3-4, pp. 157-172, 2009.
26. S. Florquin, J. G. van den Berg, D. P. Olszyna et al., "Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia, " Kidney International, vol. 59, no. 6, pp. 2054-2061, 2001.
27. C. Wei, C. C. Möller, M. M. Altintas et al., "Modification of kidney barrier function by the urokinase receptor, " Nature Medicine, vol. 14, no. 1, pp. 55-63, 2008.
28. H. W. Smith and C. J. Marshall, "Regulation of cell signalling by uPAR, " Nature Reviews Molecular Cell Biology, vol. 11, no. 1, pp. 23-36, 2010.
29. F. Blasi and P. Carmeliet, "uPAR: a versatile signalling orchestrator, " Nature Reviews Molecular Cell Biology, vol. 3, no. 12, pp. 932-943, 2002.
30. M. Nebuloni, L. Zawada, A. Ferri et al., "HIV-1 infected lymphoid organs upregulate expression and release of the cleaved formof uPAR that modulates chemotaxis and virus expression, " PLoS ONE, vol. 8, no. 7, Article ID e70606, 2013.
31. T. K. Outinen, L. Tervo, S. Mäkelä et al., "Plasma levels of soluble urokinase-type plasminogen activator receptor associate with the clinical severity of acute Puumala hantavirus infection, " PLoS ONE, vol. 8, no. 8, Article ID e71335, 2013.
32. P. Rabna, A. Andersen, C. Wejse et al., "Utility of the plasma level of suPAR in monitoring risk of mortality during TB treatment, " PLoS ONE, vol. 7, no. 8, Article ID e43933, 2012.
33. O. Slot, N. Brünner, H. Locht, P. Oxholm, and R. W. Stephens, "Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis, " Annals of the Rheumatic Diseases, vol. 58, no. 8, pp. 488-492, 1999.
34. Y. Backes, K. F. van der Sluijs, D. P. Mackie et al., "Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review, " Intensive Care Medicine, vol. 38, no. 9, pp. 1418-1428, 2012.
35. S. Lyngbak, J. L. Marott, T. Sehestedt et al., "Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score, " International Journal of Cardiology, vol. 167, no. 6, pp. 2904-2911, 2013.
36. M. Persson, G. Engström, H. Björkbacka, and B. Hedblad, "Soluble urokinase plasminogen activator receptor in plasma is associated with incidence ofCVD. Results fromtheMalmöDiet and Cancer Study, " Atherosclerosis, vol. 220, no. 2, pp. 502-505, 2012.
37. S. Lyngbak, J. L. Marott, D. V. Moller et al., "Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with stsegment elevation myocardial infarction undergoing primary percutaneous intervention, " The American Journal of Cardiology, vol. 110, no. 12, pp. 1756-1763, 2012.
38. S. Lyngbak, C. Andersson, J. L. Marott et al., "Soluble urokinase plasminogen activator receptor for risk prediction in patients admitted with acute chest pain, " Clinical Chemistry, vol. 59, no. 11, pp. 1621-1629, 2013.
39. A. Koch, S. Voigt, C. Kruschinski et al., "Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients, " Critical Care, vol. 15, article R63, 2011.
40. B. Meijers, R. Poesen, K. Claes et al., "Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease, " Kidney International, vol. 87, no. 1, pp. 210-216, 2015.
41. J. M. Spinale, L. H. Mariani, S. Kapoor et al., "A reassessment of soluble urokinase-type plasminogen activator receptor in glomerular disease, " Kidney International, vol. 87, no. 3, pp. 564-574, 2015.
42. B. Meijers, R. J. H. Maas, B. Sprangers et al., "The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis, " Kidney International, vol. 85, no. 3, pp. 636-640, 2014.
43. A. Sinha, J. Bajpai, S. Saini et al., "Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children, " Kidney International, vol. 85, no. 3, pp. 649-658, 2014.
44. T. Wada, M. Nangaku, S. Maruyama et al., "A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease, " Kidney International, vol. 85, no. 3, pp. 641-648, 2014.
45. S. S. Hayek, S. Sever, Y. A. Ko et al., "Soluble urokinase receptor and chronic kidney disease, "The New England Journal of Medicine, vol. 373, no. 20, pp. 1916-1925, 2015.
46. C. Wei, S. ElHindi, J. Li et al., "Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis, " Nature Medicine, vol. 17, no. 8, pp. 952-960, 2011.
47. C. Wei, H. Trachtman, J. Li et al., "Circulating suPAR in two cohorts of primary FSGS, " Journal of the American Society of Nephrology, vol. 23, no. 12, pp. 2051-2059, 2012.
48. F. Li, C. Zheng, Y. Zhong et al., "Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS, " Clinical Journal of the American Society of Nephrology, vol. 9, no. 11, pp. 1903-1911, 2014.
49. J. Huang, G. Liu, Y.-M. Zhang et al., "Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis, " BMC Medicine, vol. 12, no. 1, article 81, 2014.
50. R. J. H. Maas, J. F. M. Wetzels, and J. K. J. Deegens, "Serumsoluble urokinase receptor concentration in primary FSGS, " Kidney International, vol. 81, no. 10, pp. 1043-1044, 2012.
51. M. E. Bock, H. E. Price, L. Gallon, and C. B. Langman, "Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report, " Clinical Journal of the American Society of Nephrology, vol. 8, no. 8, pp. 1304-1311, 2013.
52. Y. Harita, K. Ishizuka, A. Tanego et al., "Decreased glomerular filtration as the primary factor of elevated circulating suPAR levels in focal segmental glomerulosclerosis, " Pediatric Nephrology, vol. 29, pp. 1553-1560, 2014.
53. B. K. Meijers and J. Reiser, "Reassessing the reassessment of suPAR in glomerular disease, " Frontiers in Medicine, vol. 1, article 59, 2014.
54. C.-C. Yu, A. Fornoni, A. Weins et al., "Abatacept in B7-1-positive proteinuric kidney disease, " The New England Journal of Medicine, vol. 369, no. 25, pp. 2416-2423, 2013.
55. A. Benigni, E. Gagliardini, and G. Remuzzi, "Abatacept in B7-1-positive proteinuric kidney disease, " The New England Journal of Medicine, vol. 370, no. 13, pp. 1261-1263, 2014.
56. M. Delville, E. Baye, A. Durrbach et al., "B7-1 blockade does not improve post-transplant nephrotic syndrome caused by recurrent FSGS, " Journal of theAmerican Society of Nephrology, 2015.
57. M. Alfano, P. Cinque, G. Giusti et al., "Full-length soluble urokinase plasminogen activator receptor down-modulates nephrin expression in podocytes, " Scientific Reports, vol. 5, article 13647, 2015.
58. M. Delville, T. K. Sigdel, C. Wei et al., "A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation, " Science Translational Medicine, vol. 6, no. 256, Article ID256ra136, 2014.
59. D. Cathelin, S. Placier, M. Ploug et al., "Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice, " Journal of the American Society of Nephrology, vol. 25, no. 8, pp. 1662-1668, 2014.
60. V. J. Savin, M. Sharma, J. Zhou et al., "Renal and hematological effects of CLCF-1, a B-cell-stimulating cytokine of the IL-6 family, " Journal of Immunology Research, vol. 2015, Article ID 714964, 11 pages, 2015.
61. M. Sharma, J. Zhou, J. Gauchat et al., "Janus kinase 2/signal transducer and activator of transcription 3 inhibitors attenuate the effect of cardiotrophin-like cytokine factor 1 and human focal segmental glomerulosclerosis serum on glomerular filtration barrier, " Translational Research, vol. 166, no. 4, pp. 384-398, 2015.
62. V. J. Savin, R. Sharma, H. B. Lovell, and D. J. Welling, "Measurement of albumin reflection coefficient with isolated rat glomeruli, " Journal of the American Society of Nephrology, vol. 3, no. 6, pp. 1260-1269, 1992.
63. M. Sharma, R. Sharma, E. T. McCarthy, and V. J. Savin, "The focal segmental glomerulosclerosis permeability factor: biochemical characteristics and biological effects, " Experimental Biology and Medicine, vol. 229, no. 1, pp. 85-98, 2004.
64. H. Trachtman, S. Vento, E. Herreshoff et al., "Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group, " BMC Nephrology, vol. 16, no. 1, article 111, 2015.
65. E. T. McCarthy, M. Sharma, and V. J. Savin, "Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis, " Clinical Journal of the American Society of Nephrology, vol. 5, no. 11, pp. 2115-2121, 2010.
66. K. Sgambat, M. Banks, and A. Moudgil, "Effect of galactose on glomerular permeability and proteinuria in steroid-resistant nephrotic syndrome, " Pediatric Nephrology, vol. 28, no. 11, pp. 2131-2135, 2013.
67. E. De Smet, J.-P. Rioux, H. Ammann, C. Déziel, and S. Quérin, "FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy, " Nephrology Dialysis Transplantation, vol. 24, no. 9, pp. 2938-2940, 2009.
68. M. Kopac, A. Meglic, and R. R. Rus, "Partial remission of resistant nephrotic syndrome after oral galactose therapy, " Therapeutic Apheresis and Dialysis, vol. 15, no. 3, pp. 269-272, 2011.
69. A. Chatzigeorgiou, M. Lyberi, G. Chatzilymperis, A. Nezos, and E. Kamper, "CD40/CD40L signaling and its implication in health and disease, " Biofactors, vol. 35, no. 6, pp. 474-483, 2009.
70. C. A. Janeway Jr., P. Travers, M. Walport et al., "Antigen recognition by B-cell and T-cell receptors, " in Immunobiology: The Immune System in Health and Disease, chapter 3, Garland Science, New York, NY, USA, 2001.
71. T. Wada and M. Nangaku, "A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues, " Clinical Kidney Journal, vol. 8, no. 6, pp. 708-715, 2015.